Sign in to add mentor
Adrian C. Hayday grad student 1990-1997 Yale (Cell Biology Tree)
 (The development of murine dendritic epidermal T cells.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Obst-Sander U, Ricci A, Kuhn B, et al. (2022) Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Journal of Medicinal Chemistry
Riely GJ, Lovly CM, Messina CG, et al. (2019) Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. Journal of Clinical Oncology. 37: 9062-9062
Riely G, Lovly C, Messina C, et al. (2019) P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles Journal of Thoracic Oncology. 14
Horn L, Gettinger S, Camidge DR, et al. (2017) Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer (Amsterdam, Netherlands). 113: 51-58
Arbour KC, Kris MG, Riely GJ, et al. (2017) Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer
Ichihara E, Westover D, Meador CB, et al. (2017) SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Research
Hartmaier RJ, Charo J, Fabrizio D, et al. (2017) Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9: 16
Polosukhina D, Love HD, Correa H, et al. (2017) Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. Molecular Oncology
Smit E, Soria J, Janjigian Y, et al. (2017) Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: The story so far Annals of Oncology. 28: ii30-ii31
Yu HA, Sima C, Feldman D, et al. (2016) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology
See more...